Agilent Technologies Inc. (NYSE:A) shares were down 3.6% during trading on Thursday . The company traded as low as $46.09 and last traded at $46.69, with a volume of 2,981,907 shares changing hands. The stock had previously closed at $48.43.

A number of analysts have recently weighed in on the company. Goldman Sachs Group Inc. reiterated a “buy” rating and set a $50.00 target price on shares of Agilent Technologies in a research report on Thursday. Leerink Swann reiterated an “outperform” rating and set a $51.00 target price on shares of Agilent Technologies in a research report on Thursday, June 30th. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Tuesday, May 10th. BTIG Research assumed coverage on Agilent Technologies in a research report on Friday, July 22nd. They set a “buy” rating and a $55.00 target price for the company. Finally, Barclays PLC reiterated a “hold” rating and set a $45.00 target price on shares of Agilent Technologies in a research report on Wednesday, June 8th. Seven analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $47.61.

The company has a market capitalization of $15.50 billion and a P/E ratio of 33.87. The firm’s 50 day moving average is $46.83 and its 200 day moving average is $42.59.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 17th. The company reported $0.49 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.47 by $0.02. The company earned $1.04 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same quarter last year, the firm posted $0.44 earnings per share. Agilent Technologies’s revenue for the quarter was up 3.0% compared to the same quarter last year. Equities analysts expect that Agilent Technologies Inc. will post $1.91 EPS for the current year.

In other news, Director James Cullen sold 16,922 shares of Agilent Technologies stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $44.63, for a total value of $755,228.86. Following the completion of the transaction, the director now directly owns 84,541 shares in the company, valued at $3,773,064.83. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

A number of institutional investors have bought and sold shares of A. RS Investment Management Co. LLC boosted its position in Agilent Technologies by 44.8% in the fourth quarter. RS Investment Management Co. LLC now owns 1,883,670 shares of the company’s stock valued at $78,756,000 after buying an additional 582,400 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Agilent Technologies by 43.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 164,500 shares of the company’s stock valued at $6,878,000 after buying an additional 49,900 shares during the last quarter. Schroder Investment Management Group acquired a new position in Agilent Technologies during the fourth quarter valued at approximately $1,631,000. Westfield Capital Management Co. LP boosted its position in Agilent Technologies by 9.0% in the fourth quarter. Westfield Capital Management Co. LP now owns 852,544 shares of the company’s stock valued at $35,645,000 after buying an additional 70,044 shares during the last quarter. Finally, BlackRock Advisors LLC boosted its position in Agilent Technologies by 20.6% in the fourth quarter. BlackRock Advisors LLC now owns 1,436,820 shares of the company’s stock valued at $60,074,000 after buying an additional 245,066 shares during the last quarter.

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.